Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-02-12 | Mr. Matthew P. KowalskyChief Legal Officer & Corporate Secretary | -1,90k | 27,10k | Sale to Issuer | 14,25 | 3,59k | -34,63% |
| 2026-02-12 | Mr. Brendan LuuChief Business Officer | -3,26k | 46,41k | Sale to Issuer | 14,25 | 37,01k | -8,09% |
| 2026-02-12 | Ms. Tara Lynn KiefferChief Product Strategy Officer | -3,26k | 46,41k | Sale to Issuer | 14,25 | 29,30k | -10,00% |
| 2026-02-12 | Dr. Scott T. RottinghausChief Medical Officer | -3,41k | 48,64k | Sale to Issuer | 14,25 | 18,50k | -15,57% |
| 2026-02-12 | Dr. Yat Sun OrChief Scientific Officer | -3,41k | 48,64k | Sale to Issuer | 14,25 | 369,60k | -0,91% |
| 2026-02-12 | Dr. Jay R. LulyPresident, CEO & Director | -6,16k | 87,71k | Sale to Issuer | 14,25 | 856,12k | -0,71% |
| 2025-12-05 | Ms. Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer | -323,00 | 4,60k | Verkauf | 14,23 | 1,43k | -18,44% |
| 2025-12-05 | Mr. Harry R. TroutVP of Finance & Interim Principal Financial Officer | -542,00 | 7,71k | Verkauf | 14,23 | 3,15k | -14,68% |
| 2025-12-05 | Dr. Scott T. RottinghausChief Medical Officer | -798,00 | 11,36k | Verkauf | 14,23 | 15,04k | -5,04% |
| 2025-12-05 | Mr. Brendan LuuChief Business Officer | -1,39k | 19,84k | Verkauf | 14,23 | 33,70k | -3,97% |
| 2025-12-05 | Ms. Tara Lynn KiefferChief Product Strategy Officer | -2,11k | 29,97k | Verkauf | 14,23 | 26,00k | -7,49% |
| 2025-12-05 | Dr. Yat Sun OrChief Scientific Officer | -2,39k | 34,01k | Verkauf | 14,23 | 366,14k | -0,65% |
| 2025-12-05 | Dr. Jay R. LulyPresident, CEO & Director | -4,74k | 67,49k | Verkauf | 14,23 | 826,53k | -0,57% |
| 2025-12-02 | Ms. Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer | -207,00 | 2,89k | Verkauf | 13,96 | 690,00 | -23,08% |
| 2025-12-01 | Ms. Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer | -85,00 | 1,20k | Sale to Issuer | 14,12 | 690,00 | -10,97% |
| 2025-12-02 | Mr. Harry R. TroutVP of Finance & Interim Principal Financial Officer | -380,00 | 5,30k | Verkauf | 13,96 | 1,91k | -16,61% |
| 2025-12-01 | Mr. Harry R. TroutVP of Finance & Interim Principal Financial Officer | -105,00 | 1,48k | Sale to Issuer | 14,12 | 1,91k | -5,22% |
| 2025-12-01 | Mr. Brendan LuuChief Business Officer | -498,00 | 7,03k | Sale to Issuer | 14,12 | 30,47k | -1,61% |
| 2025-12-01 | Ms. Tara Lynn KiefferChief Product Strategy Officer | -753,00 | 10,63k | Sale to Issuer | 14,12 | 23,48k | -3,11% |
| 2025-12-01 | Dr. Yat Sun OrChief Scientific Officer | -753,00 | 10,63k | Sale to Issuer | 14,12 | 363,28k | -0,21% |
| 2025-12-01 | Dr. Jay R. LulyPresident, CEO & Director | -1,89k | 26,62k | Sale to Issuer | 14,12 | 831,27k | -0,23% |
| 2025-08-08 | Dr. Scott T. RottinghausChief Medical Officer | -2,22k | 15,50k | Sale to Issuer | 6,99 | 14,09k | -13,60% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
